Emily Adams to Research Design
This is a "connection" page, showing publications Emily Adams has written about Research Design.
Connection Strength
0.035
-
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021 11 12; 76(12):3286-3295.
Score: 0.018
-
Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol. BMJ Open. 2021 03 17; 11(3):e048317.
Score: 0.017